Key Highlights
- IMUX reported a Q3 net loss of US$42,309 thousand, or US$0.99 per share.
- General and administrative expenses were US$19,421 thousand versus US$5,981 thousand.
- Research and development expenses were US$23,948 thousand versus US$20,012 thousand.
- Cash and cash equivalents were approximately US$132.0 million at September 30, 2026.
IMUX filed its Quarterly Report on November 13, 2026, for the three and nine months ended September 30, 2026. Research and Development expenses were US$23,948 thousand, versus US$20,012 thousand, an increase of 20%. The company itemized the US$3.9 million increase as US$1.9 million of higher personnel expenses, of which US$0.6 million was non-cash stock compensation, US$1.4 million for vidofludimus calcium drug supply, US$2.9 million for NDA readiness activities, US$0.3 million for drug-drug interaction studies supporting a potential NDA filing, and US$0.2 million across other categories.
These increases were partly offset by a US$1.8 million decrease for its ENSURE Clinical Trials and a US$1.0 million decrease for its CALLIPER clinical trial.
General and Administrative Costs and Net Loss
General and administrative expenses were US$19,421 thousand versus US$5,981 thousand, an increase of US$13.4 million, or 225%. The company attributed US$11.0 million to personnel expenses, of which US$9.7 million was non-cash Stock Compensation primarily related to a separation agreement with its former CEO, plus US$1.3 million of legal and consultancy expenses and US$1.1 million across other categories.
Total operating expenses were US$43,369 thousand versus US$25,993 thousand, and the loss from operations equaled those amounts. Interest income was US$1,093 thousand versus US$419 thousand, which the company attributed to a higher average cash balance following its February 2026 private placement. Net loss was US$(42,309) thousand, or US$(0.99) per share, versus US$(25,579) thousand, or US$(1.32). Weighted average shares were 42,797,370 versus 19,389,776.
Nine-Month Results and Liquidity
For the nine months, research and development expenses were US$75,505 thousand versus US$62,914 thousand, and general and administrative expenses were US$36,426 thousand versus US$16,987 thousand. Total operating expenses were US$111,931 thousand versus US$79,901 thousand. Net loss was US$(108,996) thousand, or US$(2.83) per share, versus US$(77,872) thousand, or US$(5.45).
The company reported cash and cash equivalents of approximately US$132.0 million at September 30 and an accumulated Deficit of approximately US$717.6 million, versus US$608.6 million at December 31, 2025. It said that from inception through September 30 it raised net cash of approximately US$690.0 million from offerings of preferred stock, common stock, pre-funded warrants and Tranche rights, and that it expects its funds to support operations beyond twelve months from the date the financial statements were issued.
Quarter in Review: Regulatory Preparation and Compensation Items
IMUX's third quarter combined higher research spending, led by NDA readiness activities and drug Supply for vidofludimus calcium, with a US$9.7 million non-cash stock compensation charge in general and administrative expenses tied to a former CEO separation agreement. The company said it has no products approved for commercial sale and has not generated Revenue from product sales.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...